The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 17)
Research Grant, 2013
It has been suggested that a nicotinic acetylcholine receptor (nAChR) agonists may restore the deficits caused by the loss of nicotinic acetylcholine subunits found in Parkinson's disease patients. We will test whether our nicotinic agonist possess therapeutic benefit in a pre-clinical model of L-DOPA induced dyskinesia. If our nicotinic agonist demonstrates efficacy in these s...
Researchers: Robert "Joe" Mather, BS
Dyskinesia Challenge, 2013
Levodopa-induced dyskinesias are abnormal involuntary movements that may develop with levodopa therapy for Parkinson's disease (PD). Recent studies on pre-clinical models showed that densensitization of the nicotinergic acetylcholine receptor by nicotine can modify striatal dopaminergic activity and ease dyskinesia. Of relevance, nicotine might best improve dyskine...
Rapid Response Innovation Awards, 2013
Cigarette smoking is associated with a lower risk of Parkinson's disease (PD), but its protective mechanism is unknown. Tobacco mosaic virus (TMV), a plant pathogen infecting more than 150 different plants (i.e. tobacco, tomatoes, peppers, and cucumbers), is present on cigarettes and in smokers' saliva. Researchers recently found that humans have antibodies against...
Researchers: Ruolan Liu, MD, PhD, MS
Rapid Response Innovation Awards, 2012
Although considerable achievements have been made in the understanding of pathophysiology of Parkinson's disease (PD), there are still limited effective approaches available for PD treatment. Thus, there are strong needs for exploring new therapeutics and approaches for PD patients. The objectives of this project are to characterize therapeutic effect of beta-cembrane, a tobac...
Researchers: Jiukuan Hao, MD/ PhD
Target Validation, 2011
The scientific community has known since 1959 that tobacco use has apparent protective effects against Parkinson’s disease (PD), and some animal models suggest that this protective effect arises from nicotine itself. Nicotine therefore represents a candidate “lead” neuroprotective drug for those diagnosed with early-stage PD. However, nicotine is a suboptimal therapeutic dr...
Researchers: Henry A. Lester, PhD